Will platelets drop after stopping eltrombopag?

Eltrombopag/Eltrombopag is mainly used to stimulate platelet production and is suitable for the treatment of chronic immune thrombocytopenia (ITP) and severe aplastic anemia. It promotes the maturation of megakaryocytes and the release of platelets in the bone marrow by activating the thrombopoietin receptor (TPO-R), thereby increasing peripheral platelet levels. Because the drug is an oral formulation, it is easy to take and has practical utility in the long-term management of thrombocytopenia-related diseases.

In clinical applications, the dose and duration of eltrombopag need to be adjusted based on the patient's platelet count and individual response. Doctors usually start with a low dose and gradually adjust to the minimum dose that is effective to reduce the risk of side effects. Some patients have stable platelet counts after maintenance treatment, can achieve long-term disease control, and improve bleeding risk and quality of life.

However, concerns have also been raised about reactions after drug withdrawal. The effect of eltrombopag mainly depends on its activation of TPO receptors. Therefore, once you stop taking it, the stimulating effect will weaken or even disappear. Some patients may experience platelet withdrawal after discontinuation of the drug, especially in individuals where the drug does not adequately maintain hematopoietic reconstitution. This kind of "rebound decline after drug withdrawal" is not uncommon, especially in the early stages of treatment. Doctors usually do not recommend stopping the drug suddenly, but instead use a gradual reduction and close monitoring to withdraw the drug.

However, some studies have found that some patients who responded well to eltrombopag gradually recovered their hematopoietic system function after long-term use. Even if the drug is stopped, platelets can remain relatively stable for a period of time. This suggests that the drug may have the potential to reshape bone marrow function in some patients, but this still requires more clinical validation.

Reference materials:https://go.drugbank.com/drugs/DB06210